ATE539757T1 - Verfahren zur hemmung von nkt-zellen - Google Patents

Verfahren zur hemmung von nkt-zellen

Info

Publication number
ATE539757T1
ATE539757T1 AT05851383T AT05851383T ATE539757T1 AT E539757 T1 ATE539757 T1 AT E539757T1 AT 05851383 T AT05851383 T AT 05851383T AT 05851383 T AT05851383 T AT 05851383T AT E539757 T1 ATE539757 T1 AT E539757T1
Authority
AT
Austria
Prior art keywords
nkt cell
treatment
nkt cells
inhibiting
galactosylceramide
Prior art date
Application number
AT05851383T
Other languages
English (en)
Inventor
Samuel Strober
Everett Hurteau Meyer
Dale T Umetsu
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE539757T1 publication Critical patent/ATE539757T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7024—Esters of saccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
AT05851383T 2004-11-02 2005-11-02 Verfahren zur hemmung von nkt-zellen ATE539757T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US62456804P 2004-11-02 2004-11-02
US70654805P 2005-08-08 2005-08-08
PCT/US2005/040182 WO2006060117A2 (en) 2004-11-02 2005-11-02 Methods for inhibition of nkt cells

Publications (1)

Publication Number Publication Date
ATE539757T1 true ATE539757T1 (de) 2012-01-15

Family

ID=36565493

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05851383T ATE539757T1 (de) 2004-11-02 2005-11-02 Verfahren zur hemmung von nkt-zellen

Country Status (11)

Country Link
US (2) US7682614B2 (de)
EP (1) EP1812015B1 (de)
JP (1) JP4948418B2 (de)
CN (1) CN101031307B (de)
AT (1) ATE539757T1 (de)
AU (1) AU2005310247A1 (de)
CA (1) CA2584971C (de)
DK (1) DK1812015T3 (de)
ES (1) ES2378076T3 (de)
PT (1) PT1812015E (de)
WO (1) WO2006060117A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002076401A2 (en) 2001-03-26 2002-10-03 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
WO2011149881A2 (en) * 2010-05-24 2011-12-01 Children's Medical Center Corporation Methods for the treatment and prevention of inflammatory diseases
RU2603075C2 (ru) * 2010-11-25 2016-11-20 Имнейт Сарл Изменение иммуногенности антигена путем введения эпитопов, узнаваемых nkt-клетками
WO2013009945A1 (en) 2011-07-12 2013-01-17 The Brigham And Women's Hospital, Inc. Lipid-containing psa compositions, methods of isolation and methods of use thereof
JP2015502340A (ja) * 2011-10-27 2015-01-22 エヌケーティー セラピューティクス インコーポレーテッドＮｋｔ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｉｎｃ． ｉＮＫＴに対するヒト化抗体
US10329315B2 (en) 2012-10-12 2019-06-25 The Brigham And Women's Hospital, Inc. Glycosphingolipids and methods of use thereof
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
CN105473133A (zh) 2013-04-30 2016-04-06 欧缇托匹克公司 干粉制剂及使用方法
CN108135167B (zh) 2015-08-19 2021-07-09 哈佛学院院长及董事 脂化psa组合物和方法
CA3030974A1 (en) 2016-07-15 2018-01-18 President And Fellows Of Harvard College Glycolipid compositions and methods of use
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
KR20230040375A (ko) 2017-09-22 2023-03-22 오티토픽 인코퍼레이티드 스테아르산마그네슘을 갖는 건조 분말 조성물
WO2023153527A1 (ja) * 2022-02-14 2023-08-17 国立研究開発法人理化学研究所 Ｎｋｔ細胞リガンド含有リポソーム組成物

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
US5679347A (en) 1992-12-10 1997-10-21 Brigham And Women's Hospital Methods of isolating CD1-presented antigens, vaccines comprising CD1-presented antigens, and cell lines for use in said methods
US7063844B2 (en) 1992-12-10 2006-06-20 The Brigham And Women's Hospital, Inc. Presentation of hydrophobic antigens to T-cells by CD1 molecules
CA2165786A1 (en) 1993-06-21 1995-01-05 Steven A. Porcelli Methods of isolating cd1-presented antigens, vaccines comprising cd1-presented antigens, and cell lines for use in said methods
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
CN1222293C (zh) 1997-04-10 2005-10-12 麒麟麦酒株式会社 含有α－糖基神经酰胺的NKT细胞活化剂
ZA988333B (en) 1997-09-12 1999-03-23 Brigham & Woman S Hospital Synthetic antigens for CD1-restricted immune responses
TW575420B (en) 1997-09-22 2004-02-11 Kirin Brewery Composition for enhancing cellular immunogenicity comprising alpha-glycosylceramides
US6197582B1 (en) 1998-03-18 2001-03-06 The Trustees Of Columbia University In The City Of New York Development of human monoclonal antibodies and uses thereof
DE69933218D1 (de) 1998-07-09 2006-10-26 Brian J Nickoloff Methode zur behandlung von krankheiten durch veränderung der wechselwirkung zwischen natural killer rezeptoren auf t-zellen mit ihren jeweiligen liganden
US20010051156A1 (en) 2000-04-28 2001-12-13 Defu Zeng Methods for inhibition of polyclonal B cell activation and immunoglobulin class switching to pathogenic autoantibodies by blocking CD1-mediated interactions
US20020071842A1 (en) 2000-06-05 2002-06-13 Gumperz Jenny E. Soluble CD1 compositions and uses thereof
EP1288291A4 (de) 2000-06-06 2004-05-12 Kirin Brewery Methode zur verfielfältigung von natürlichen killer-t-zellen
ES2586206T3 (es) * 2000-06-19 2016-10-13 Beth Israel Deaconess Medical Center Composiciones y métodos de anticuerpos monoclonales y policlonales específicos para subpoblaciones de linfocitos T
WO2001098317A2 (en) 2000-06-22 2001-12-27 The Brigham And Women's Hospital, Inc. Alpha-glycosylceramides for treating bacterial and fungal infections
US6867673B2 (en) 2000-08-18 2005-03-15 Mitsubishi Denki Kabushiki Kaisha Socket for lamp, transformer for lamp and method of manufacturing transformer for lamp
DE10046658A1 (de) 2000-09-20 2002-04-04 Bosch Gmbh Robert Induktiver Übertrager und ein Verfahren zu dessen Herstellung
JP3523245B1 (ja) 2000-11-30 2004-04-26 メダレックス，インコーポレーテッド ヒト抗体作製用トランスジェニック染色体導入齧歯動物
IL140537A0 (en) 2000-12-25 2002-02-10 Hadasit Med Res Service Educated nk t cells and their uses in the treatment of immune-related disorders
WO2002076401A2 (en) 2001-03-26 2002-10-03 Dana-Farber Cancer Institute, Inc. Method of attenuating reactions to skin irritants
US8178098B2 (en) * 2001-04-03 2012-05-15 National Jewish Health Method to inhibit airway hyperresponsiveness using aerosolized T cell receptor antibodies
US6662434B2 (en) 2001-04-03 2003-12-16 General Electric Company Method and apparatus for magnetizing a permanent magnet
CA2444429A1 (en) 2001-04-11 2002-11-07 Atherogenics, Inc. Probucol monoesters and their use to increase plasma hdl cholesterol levels and improve hdl functionality
US20020171538A1 (en) 2001-05-15 2002-11-21 Kuo-Hsin Su Vehicle motion detector and control device arrangement
US20020171557A1 (en) 2001-05-18 2002-11-21 Wegener William E. Security electronic system
WO2003009812A2 (en) 2001-07-25 2003-02-06 New York University Use of glycosylceramides as adjuvants for vaccines against infections and cancer
WO2003092615A2 (en) 2002-05-01 2003-11-13 Beth Israel Deaconess Medical Center Use of anti-cd1 antibodies for the modulation of immune responses
CA2493690C (en) 2002-06-13 2011-11-08 New York University Synthetic c-glycolipid and its use for treating cancer, infectious diseases and autoimmune diseases
JP4689268B2 (ja) 2002-06-14 2011-05-25 ザ ガバメント オブ ザ ユナイテッド ステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー オブ ザ デパートメント オブ ヘルス アンド ヒューマン サービシーズ Ｉｌ−１３およびｎｋ−ｔ細胞に関する、結腸炎を処置および予防する方法
US7368142B2 (en) 2002-08-01 2008-05-06 Renew Life Formulas, Inc. Natural sweetener
BR0313808A (pt) 2002-08-27 2005-07-05 Nestle Sa Prevenção ou tratamento de lesão de tecidos epiteliais ou queda de cabelo
CA2500478A1 (en) 2002-09-27 2004-04-08 Biomira, Inc. Glycosylceramide analogues
US20040171522A1 (en) 2003-02-27 2004-09-02 Yaron Ilan Regulation of immune responses by manipulation of intermediary metabolite levels
US9717754B2 (en) * 2003-02-27 2017-08-01 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
WO2005032462A2 (en) * 2003-02-27 2005-04-14 Enzo Therapeutics, Inc. Glucocerebroside treatment of disease
US20050032210A1 (en) 2003-03-18 2005-02-10 Kirin Beer Kabushiki Kaisha Method of preparing immuno-regulatory dendritic cells and the use thereof
US20040235162A1 (en) 2003-03-18 2004-11-25 Kirin Beer Kabushiki Kaisha Method of preparing immunoregulatory dendritic cells and the use thereof
EP1611147A4 (de) * 2003-03-20 2007-10-17 Univ Brigham Young 6"-amino-6"-deoxygalactosylceramide
WO2004084874A2 (en) 2003-03-24 2004-10-07 Brigham And Women's Hospital, Inc. Mtp inhibitors for inhibiting inflammation
WO2005014008A2 (en) 2003-07-17 2005-02-17 The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Treatment of disorders associated with natural killer t cells
EP1767216B1 (de) 2004-06-11 2012-07-11 Riken Arzneimittel mit regulierendem zellliganden in einem liposom

Also Published As

Publication number Publication date
AU2005310247A1 (en) 2006-06-08
EP1812015A4 (de) 2008-02-20
CA2584971A1 (en) 2006-06-08
ES2378076T3 (es) 2012-04-04
EP1812015A2 (de) 2007-08-01
US20060116332A1 (en) 2006-06-01
CA2584971C (en) 2013-08-06
CN101031307A (zh) 2007-09-05
CN101031307B (zh) 2012-09-05
DK1812015T3 (en) 2013-01-02
EP1812015B1 (de) 2012-01-04
WO2006060117A3 (en) 2007-03-01
PT1812015E (pt) 2012-02-20
JP4948418B2 (ja) 2012-06-06
JP2008518974A (ja) 2008-06-05
US20100197613A1 (en) 2010-08-05
US7682614B2 (en) 2010-03-23
US8679499B2 (en) 2014-03-25
WO2006060117A2 (en) 2006-06-08

Similar Documents

Publication Publication Date Title
ATE539757T1 (de) Verfahren zur hemmung von nkt-zellen
Sielaff et al. Evaluation of FASP, SP3, and iST protocols for proteomic sample preparation in the low microgram range
BR112014018210A2 (pt) moléculas de ácido nucleico artificiais para expressão de proteína ou peptídeo melhorada
BR112014032999A2 (pt) optimização de anticorpos que ligam o gene de ativação de linfócito 3 (lag-3), e uso dos mesmos
Barbieri et al. Creatine prevents the structural and functional damage to mitochondria in myogenic, oxidatively stressed C2C12 cells and restores their differentiation capacity
MA42381A (fr) Nouveaux peptides et nouvelle combinaison de peptides à utiliser dans l'immunothérapie du cancer de l' oesophage et d'autres cancers
BR112018011781A2 (pt) molécula biespecífica possuindo um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de pd-1 e um ou mais sítios de ligação a epítopo capazes de ligação imunoespecífica a (um) epítopo(s) de ctla-4, e composição farmacêutica
Na et al. Bone marrow-derived clonal mesenchymal stem cells inhibit ovalbumin-induced atopic dermatitis
CL2018000622A1 (es) Acetamida tienodiazepinas de triazol y sus usos relacionados.
UA117216C2 (uk) Пухлиноасоційований пептид та його застосування
WO2008137758A3 (en) Amino acid lipids and uses thereof
CL2013002062A1 (es) Anticuerpo monoclonal que se une al gen 3 de la activacion linfocitaria (lag-3) humana; composicion que comprende dicho anticuerpo; molecula de acido nucleico que lo codifica; vector de expresion y celula huesped que lo comprende: metodo de preparacion; y su uso para estimular la respuesta inmune.
BR112018003316A2 (pt) compostos e métodos para entrega transmembrana de moléculas
MA46647A1 (fr) Nouveaux peptides et combinaison de peptides à utiliser dans l'immunothérapie du cancer du pancréas et d'autres cancers
Ruiz-Miyazawa et al. Hesperidin methylchalcone suppresses experimental gout arthritis in mice by inhibiting NF-κB activation
EA200501592A1 (ru) Способы и композиции для введения агонистов trpv1
EA201000424A1 (ru) Антитела к il-23
BR112012022223A2 (pt) formulações de proteína concentrada e usos das mesmas
UY31114A1 (es) Anticuerpos humanizados contra el globulómero ab(20-42) y sus usos
EP3699172A3 (de) Neuartige lipide und zusammensetzungen zur verabreichung von therapeutika
WO2004074434A3 (en) Methods and compositions for administering therapeutic and diagnostic agents
UY32691A (es) Compuestos de 1h-imidazo-[4,5-c]-quinolinona
BR112012028648A2 (pt) uso cosmético de sulfoniloxibenzilaminas substituídas por n e compostos relacionados
BR112012010333A2 (pt) peptídeos terapêuticos
BRPI0514124B8 (pt) anticorpos monoclonais específicos para il-4 humana, seu uso, composição farmacêutica que os comprende e polinucleotídeos